3/26/2012 2:00:00 PM

Bayer: Committed to contribute in the fight against Neglected Tropical Diseases

  • Bayer extends donation to fight Chagas and Sleeping sickness
  • Bayer Experts exchange on fighting Chagas disease in children

At the end of January, 13 pharmaceutical companies including Bayer as well as the U.S., U.K. and U.A.E governments, the Bill & Melinda Gates Foundation, the World Bank and other global health organisations announced at a joint meeting in London a new, coordinated push to accelerate progress toward eliminating or controlling 10 Neglected Tropical Diseases (NTDs) by the end of the decade. To support the worldwide efforts Bayer announced that it would support the initiative and committed itself to double the existing amount of Nifurtimox to effectively combat Chagas Disease.

Bayer's valid agreement with WHO to provide Suramin and Nifurtimox, to treat Sleeping Sickness, will be extended until 2020. Additionally Bayer will give access to selected substances to third parties, including the R&D organisation “Drugs for Neglected Diseases initiative” (DNDi), out of its compound libraries to find new treatments for NTDs. (For further details, please click on the image)

Building up on Bayer’s existing engagement with Chagas disease in Latin America, the company recently convened an expert meeting to assess how Bayer can best leverage its competencies to fight Chagas in children. Experts from Bayer HealthCare, Bayer CropScience and Bayer MaterialScience discussed the best ways to join forces.

The broad experience and portfolio of Bayer solutions, ranging from pharmaceuticals, Animal Health as well as from Material Science and Vector Control activities provides us with outstanding opportunities to engage in the fight against this disease”, Gerhard Hesse, Head of Global Partnering / Vector Control at Bayer CropScience, comments about the meeting. “Aligning our priorities across all subgroups was one more important step towards an even more targeted engagement” .

Dr. Gerhard Hesse explains that Bayer has an opportunity to use its unique broad expertise in curative therapies and in preventive vector control interventions. According to him this was a very important meeting to find a common ground and help different Bayer teams identify a joint approach to fight this tropical disease.

“With the London Declaration Bayer renewed its commitment to control Chagas disease, translating the commitment into programs. I am personally confident that elimination is reachable with a strategy combining global, regional and national interests.”

For more information on Bayer’s commitment to Vector Control please contact Dr. Gerhard Hesse